Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Luís Coelho; Fatima Falcão; Pedro Póvoa; Erica Viegas; Antonio Pais Martins; Eduarda Carmo; Candida Fonseca; Luis Campos; Kamal Mansinho; Inês Carmo; Joana Soares; Mariana Solano; Dina Mendes; Ana Cláudia Miranda; Antonio Carvalho; Ana Mirco; Helena Farinha; Isabel Aldir; José Correia

doi:10.1038/s41598-023-31544-5

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Luís Coelho, Fatima Falcão, Pedro Póvoa, Erica Viegas, Antonio Pais Martins, Eduarda Carmo, Candida Fonseca, Luis Campos, Kamal Mansinho, Inês Carmo, Joana Soares, Mariana Solano, Dina Mendes, Ana Cláudia Miranda, Antonio Carvalho, Ana Mirco, Helena Farinha, Isabel Aldir, José Correia

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

23 Downloads (Pure)

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

Original language	English
Article number	4482
Pages (from-to)	4482
Number of pages	1
Journal	Scientific Reports
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41598-023-31544-5
Publication status	Published - 18 Mar 2023

Access to Document

10.1038/s41598-023-31544-5

s41598-023-31544-5Final published version, 1.13 MBLicence: CC BY

Cite this

Coelho, L., Falcão, F., Póvoa, P., Viegas, E., Martins, A. P., Carmo, E., Fonseca, C., Campos, L., Mansinho, K., Carmo, I., Soares, J., Solano, M., Mendes, D., Miranda, A. C., Carvalho, A., Mirco, A., Farinha, H., Aldir, I., & Correia, J. (2023). Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. Scientific Reports, 13(1), 4482. Article 4482. https://doi.org/10.1038/s41598-023-31544-5

@article{4ecce467ccb24c53a7b4fa02b3cd54e9,

title = "Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients",

abstract = "Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.",

author = "Lu{\'i}s Coelho and Fatima Falc{\~a}o and Pedro P{\'o}voa and Erica Viegas and Martins, {Antonio Pais} and Eduarda Carmo and Candida Fonseca and Luis Campos and Kamal Mansinho and In{\^e}s Carmo and Joana Soares and Mariana Solano and Dina Mendes and Miranda, {Ana Cl{\'a}udia} and Antonio Carvalho and Ana Mirco and Helena Farinha and Isabel Aldir and Jos{\'e} Correia",

note = "ok",

year = "2023",

month = mar,

day = "18",

doi = "10.1038/s41598-023-31544-5",

language = "English",

volume = "13",

pages = "4482",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Coelho, L, Falcão, F, Póvoa, P , Viegas, E, Martins, AP, Carmo, E, Fonseca, C , Campos, L , Mansinho, K, Carmo, I, Soares, J, Solano, M, Mendes, D, Miranda, AC, Carvalho, A, Mirco, A, Farinha, H, Aldir, I & Correia, J 2023, 'Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients', Scientific Reports, vol. 13, no. 1, 4482, pp. 4482. https://doi.org/10.1038/s41598-023-31544-5

TY - JOUR

T1 - Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

AU - Coelho, Luís

AU - Falcão, Fatima

AU - Póvoa, Pedro

AU - Viegas, Erica

AU - Martins, Antonio Pais

AU - Carmo, Eduarda

AU - Fonseca, Candida

AU - Campos, Luis

AU - Mansinho, Kamal

AU - Carmo, Inês

AU - Soares, Joana

AU - Solano, Mariana

AU - Mendes, Dina

AU - Miranda, Ana Cláudia

AU - Carvalho, Antonio

AU - Mirco, Ana

AU - Farinha, Helena

AU - Aldir, Isabel

AU - Correia, José

N1 - ok

PY - 2023/3/18

Y1 - 2023/3/18

N2 - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

AB - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

UR - http://www.scopus.com/inward/record.url?scp=85150666465&partnerID=8YFLogxK

U2 - 10.1038/s41598-023-31544-5

DO - 10.1038/s41598-023-31544-5

M3 - Article

C2 - 36934143

AN - SCOPUS:85150666465

SN - 2045-2322

VL - 13

SP - 4482

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 4482

ER -

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this